总时间（秒）：11894.82
问答时间（秒）：1113.13

* First, I'll extract the variants and relevant portions of text for each variant. Here are the variants and the sentences where they are mentioned:


| Variant  | Relevant Sentences                                                                                                                          |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------|
| C106A    | "Mutagenesis of DJ-1 Cysteine and Methionine Residues-Human DJ-1 contains 11 cysteine residues (Fig. 6A). Cys-106 is..."                    |
| M26I     | "...and M26I DJ-1 mutations produced similar spectra (Fig. 6B). The M26I DJ-1 mutation is associated with early onset Parkinson disease (PD)" |
| T175N    | "T175N, and T223P were expressed at levels similar to..."                                                                                  |
| L166P    | "...L166P, A104T, T175N, and T223P were expressed at levels similar to..."                                                                 |
| A104T    | "...L166P, A104T, T175N, and T223P were expressed at levels similar to..."                                                                 |
| T223P    | "...L166P, A104T, T175N, and T223P were expressed at levels similar to..."                                                                 |
| H126R    | "H126R, A158P, and P158A DJ-1 were expressed at..."                                                                                       |



* Now, I'll go through each step of the ACMG functional evidence evaluation flowchart for each variant:

#### Variant: C106A

**Step 1: Define the disease mechanism.**
* **Internal Judgment:** There is no explicit statement about the disease mechanism or the function of DJ-1 within it. The article focuses on DJ-1 mutations and their effects on protein stability and activity.

**Step 2: Evaluate applicability of general classes of assay used in the field.**
* **Internal Decision Logic:** Since the paper does not provide sufficient information about the disease mechanism, we cannot evaluate the applicability of the general assay class. Therefore, we proceed to Step 3.

**Step 3: Evaluate validity of specific instances of assays.**
* **Sub-step 3a: Basic Controls and Replicates.**
    * **Internal Judgment:** The paper does not mention specific controls or replicates used in the experiments. However, it states that the results shown in figures are mean values with standard errors from 2-4 independent experiments. This suggests some level of replication.

    * **Internal Decision Logic (for 3a):** Since the paper does not explicitly state whether normal/negative/wild-type and abnormal/positive/null controls were used, we proceed to Sub-step 3b.

* **Sub-step 3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a).**
    * **Internal Judgment:** The paper does not mention any specific validation studies or commercial kits used for the assays. However, it provides detailed methods and results, suggesting that the assays are standard techniques in the field.

    * **Internal Decision Logic (for 3b):** Since the assays appear to be broadly accepted in the field, we assume that the functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

* **Sub-step 3c: Variant Controls (if basic controls/replicates were sufficient in 3a).**
    * **Internal Judgment:** The paper does not mention any specific pathogenic or benign variant controls used in the experiments. However, it states that T175N and T223P were expressed at levels similar to wild-type DJ-1, which may suggest that these variants could serve as variant controls.

    * **Internal Decision Logic (for 3c):** Since the paper does not explicitly mention known pathogenic or benign variant controls, we assume that the functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

**Step 4: Apply evidence to individual variant interpretation.**
* **Sub-step 4a: Statistical Analyses.**
    * **Internal Judgment:** The paper does not provide detailed statistical analyses for the experiments. It only mentions that the results shown in figures are mean values with standard errors from 2-4 independent experiments. This suggests some level of statistical analysis, but not enough to calculate OddsPath.

    * **Internal Decision Logic (for 4a):** Since the statistical analyses are insufficient, we proceed to Sub-step 4b.

* **Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient).**
    * **Internal Judgment:** The paper does not mention any specific pathogenic or benign variant controls used in the experiments. Therefore, we cannot determine the total number of variant controls used across the study.

    * **Internal Decision Logic (for 4b):** Since the total number of variant controls is unknown, we assume that the functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

* **Sub-step 4c: Correlate OddsPath (if statistical analyses were sufficient).**
    * **Internal Judgment:** Since the statistical analyses are insufficient, we cannot extract the OddsPath value calculated in the paper for the C106A variant.

    * **Internal Decision Logic (Typical Outcomes):** Since we cannot correlate the OddsPath, we assume that the functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

**Final Assessment:**
* **Functional Evidence Type:** N/A (since we do not have sufficient information to make a definitive assessment)
* **Functional Evidence Strength:** Max PS3_supporting / Max BS3_supporting
* **Overall Conclusion:** The functional evidence for the C106A variant is considered **Max PS3_supporting / Max BS3_supporting**, as the paper does not provide sufficient information to make a more definitive assessment. However, the lack of explicit statements about the disease mechanism and the use of variant controls weaken the evidence strength.

#### Variant: M26I

**Step 1: Define the disease mechanism.**
* **Internal Judgment:** There is no explicit statement about the disease mechanism or the function of DJ-1 within it. The article focuses on DJ-1 mutations and their effects on protein stability and activity.

**Step 2: Evaluate applicability of general classes of assay used in the field.**
* **Internal Decision Logic:** Since the paper does not provide sufficient information about the disease mechanism, we cannot evaluate the applicability of the general assay class. Therefore, we proceed to Step 3.

**Step 3: Evaluate validity of specific instances of assays.**
* **Sub-step 3a: Basic Controls and Replicates.**
    * **Internal Judgment:** The paper does not mention specific controls or replicates used in the experiments. However, it states that the results shown in figures are mean values with standard errors from 2-4 independent experiments. This suggests some level of replication.

    * **Internal Decision Logic (for 3a):** Since the paper does not explicitly state whether normal/negative/wild-type and abnormal/positive/null controls were used, we proceed to Sub-step 3b.

* **Sub-step 3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a).**
    * **Internal Judgment:** The paper does not mention any specific validation studies or commercial kits used for the assays. However, it provides detailed methods and results, suggesting that the assays are standard techniques in the field.

    * **Internal Decision Logic (for 3b):** Since the assays appear to be broadly accepted in the field, we assume that the functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

* **Sub-step 3c: Variant Controls (if basic controls/replicates were sufficient in 3a).**
    * **Internal Judgment:** The paper does not mention any specific pathogenic or benign variant controls used in the experiments. However, it states that T175N and T223P were expressed at levels similar to wild-type DJ-1, which may suggest that these variants could serve as variant controls.

    * **Internal Decision Logic (for 3c):** Since the paper does not explicitly mention known pathogenic or benign variant controls, we assume that the functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

**Step 4: Apply evidence to individual variant interpretation.**
* **Sub-step 4a: Statistical Analyses.**
    * **Internal Judgment:** The paper does not provide detailed statistical analyses for the experiments. It only mentions that the results shown in figures are mean values with standard errors from 2-4 independent experiments. This suggests some level of statistical analysis, but not enough to calculate OddsPath.

    * **Internal Decision Logic (for 4a):** Since the statistical analyses are insufficient, we proceed to Sub-step 4b.

* **Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient).**
    * **Internal Judgment:** The paper does not mention any specific pathogenic or benign variant controls used in the experiments. Therefore, we cannot determine the total number of variant controls used across the study.

    * **Internal Decision Logic (for 4b):** Since the total number of variant controls is unknown, we assume that the functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

* **Sub-step 4c: Correlate OddsPath (if statistical analyses were sufficient).**
    * **Internal Judgment:** Since the statistical analyses are insufficient, we cannot extract the OddsPath value calculated in the paper for the M26I variant.

    * **Internal Decision Logic (Typical Outcomes):** Since we cannot correlate the OddsPath, we assume that the functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

**Final Assessment:**
* **Functional Evidence Type:** N/A (since we do not have sufficient information to make a definitive assessment)
* **Functional Evidence Strength:** Max PS3_supporting / Max BS3_supporting
* **Overall Conclusion:** The functional evidence for the M26I variant is considered **Max PS3_supporting / Max BS3_supporting**, as the paper does not provide sufficient information to make a more definitive assessment. However, the lack of explicit statements about the disease mechanism and the use of variant controls weaken the evidence strength.

#### Variant: T175N

**Step 1: Define the disease mechanism.**
* **Internal Judgment:** There is no explicit statement about the disease mechanism or the function of DJ-1 within it. The article focuses on DJ-1 mutations and their effects on protein stability and activity.

**Step 2: Evaluate applicability of general classes of assay used in the field.**
* **Internal Decision Logic:** Since the paper does not provide sufficient information about the disease mechanism, we cannot evaluate the applicability of the general assay class. Therefore, we proceed to Step 3.

**Step 3: Evaluate validity of specific instances of assays.**
* **Sub-step 3a: Basic Controls and Replicates.**
    * **Internal Judgment:** The paper does not mention specific controls or replicates used in the experiments. However, it states that the results shown in figures are mean values with standard errors from 2-4 independent experiments. This suggests some level of replication.

    * **Internal Decision Logic (for 3a):** Since the paper does not explicitly state whether normal/negative/wild-type and abnormal/positive/null controls were used, we proceed to Sub-step 3b.

* **Sub-step 3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a).**
    * **Internal Judgment:** The paper does not mention any specific validation studies or commercial kits used for the assays. However, it provides detailed methods and results, suggesting that the assays are standard techniques in the field.

    * **Internal Decision Logic (for 3b):** Since the assays appear to be broadly accepted in the field, we assume that the functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

* **Sub-step 3c: Variant Controls (if basic controls/replicates were sufficient in 3a).**
    * **Internal Judgment:** The paper does not mention any specific pathogenic or benign variant controls used in the experiments. However, it states that T175N and T223P were expressed at levels similar to wild-type DJ-1, which may suggest that these variants could serve as variant controls.

    * **Internal Decision Logic (for 3c):** Since the paper does not explicitly mention known pathogenic or benign variant controls, we assume that the functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

**Step 4: Apply evidence to individual variant interpretation.**
* **Sub-step 4a: Statistical Analyses.**
    * **Internal Judgment:** The paper does not provide detailed statistical analyses for the experiments. It only mentions that the results shown in figures are mean values with standard errors from 2-4 independent experiments. This suggests some level of statistical analysis, but not enough to calculate OddsPath.

    * **Internal Decision Logic (for 4a):** Since the statistical analyses are insufficient, we proceed to Sub-step 4b.

* **Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient).**
    * **Internal Judgment:** The paper does not mention any specific pathogenic or benign variant controls used in the experiments. Therefore, we cannot determine the total number of variant controls used across the study.

    * **Internal Decision Logic (for 4b):** Since the total number of variant controls is unknown, we assume that the functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

* **Sub-step 4c: Correlate OddsPath (if statistical analyses were sufficient).**
    * **Internal Judgment:** Since the statistical analyses are insufficient, we cannot extract the OddsPath value calculated in the paper for the T175N variant.

    * **Internal Decision Logic (Typical Outcomes):** Since we cannot correlate the OddsPath, we assume that the functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

**Final Assessment:**
* **Functional Evidence Type:** N/A (since we do not have sufficient information to make a definitive assessment)
* **Functional Evidence Strength:** Max PS3_supporting / Max BS3_supporting
* **Overall Conclusion:** The functional evidence for the T175N variant is considered **Max PS3_supporting / Max BS3_supporting**, as the paper does not provide sufficient information to make a more definitive assessment. However, the lack of explicit statements about the disease mechanism and the use of variant controls weaken the evidence strength.

#### Variant: L166P

**Step 1: Define the disease mechanism.**
* **Internal Judgment:** There is no explicit statement about the disease mechanism or the function of DJ-1 within it. The article focuses on DJ-1 mutations and their effects on protein stability and activity.

**Step 2: Evaluate applicability of general classes of assay used in the field.**
* **Internal Decision Logic:** Since the paper does not provide sufficient information about the disease mechanism, we cannot evaluate the applicability of the general assay class. Therefore, we proceed to Step 3.

**Step 3: Evaluate validity of specific instances of assays.**
* **Sub-step 3a: Basic Controls and Replicates.**
    * **Internal Judgment:** The paper does not mention specific controls or replicates used in the experiments. However, it states that the results shown in figures are mean values with standard errors from 2-4 independent experiments. This suggests some level of replication.

    * **Internal Decision Logic (for 3a):** Since the paper does not explicitly state whether normal/negative/wild-type and abnormal/positive/null controls were used, we proceed to Sub-step 3b.

* **Sub-step 3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a).**
    * **Internal Judgment:** The paper does not mention any specific validation studies or commercial kits used for the assays. However, it provides detailed methods and results, suggesting that the assays are standard techniques in the field.

    * **Internal Decision Logic (for 3b):** Since the assays appear to be broadly accepted in the field, we assume that the functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

* **Sub-step 3c: Variant Controls (if basic controls/replicates were sufficient in 3a).**
    * **Internal Judgment:** The paper does not mention any specific pathogenic or benign variant controls used in the experiments. However, it states that T175N and T223P were expressed at levels similar to wild-type DJ-1, which may suggest that these variants could serve as variant controls.

    * **Internal Decision Logic (for 3c):** Since the paper does not explicitly mention known pathogenic or benign variant controls, we assume that the functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

**Step 4: Apply evidence to individual variant interpretation.**
* **Sub-step 4a: Statistical Analyses.**
    * **Internal Judgment:** The paper does not provide detailed statistical analyses for the experiments. It only mentions that the results shown in figures are mean values with standard errors from 2-4 independent experiments. This suggests some level of statistical analysis, but not enough to calculate OddsPath.

    * **Internal Decision Logic (for 4a):** Since the statistical analyses are insufficient, we proceed to Sub-step 4b.

* **Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient).**
    * **Internal Judgment:** The paper does not mention any specific pathogenic or benign variant controls used in the experiments. Therefore, we cannot determine the total number of variant controls used across the study.

    * **Internal Decision Logic (for 4b):** Since the total number of variant controls is unknown, we assume that the functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

* **Sub-step 4c: Correlate OddsPath (if statistical analyses were sufficient).**
    * **Internal Judgment:** Since the statistical analyses are insufficient, we cannot extract the OddsPath value calculated in the paper for the L166P variant.

    * **Internal Decision Logic (Typical Outcomes):** Since we cannot correlate the OddsPath, we assume that the functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

**Final Assessment:**
* **Functional Evidence Type:** N/A (since we do not have sufficient information to make a definitive assessment)
* **Functional Evidence Strength:** Max PS3_supporting / Max BS3_supporting
* **Overall Conclusion:** The functional evidence for the L166P variant is considered **Max PS3_supporting / Max BS3_supporting**, as the paper does not provide sufficient information to make a more definitive assessment. However, the lack of explicit statements about the disease mechanism and the use of variant controls weaken the evidence strength.

#### Variant: A104T

**Step 1: Define the disease mechanism.**
* **Internal Judgment:** There is no explicit statement about the disease mechanism or the function of DJ-1 within it. The article focuses on DJ-1 mutations and their effects on protein stability and activity.

**Step 2: Evaluate applicability of general classes of assay used in the field.**
* **Internal Decision Logic:** Since the paper does not provide sufficient information about the disease mechanism, we cannot evaluate the applicability of the general assay class. Therefore, we proceed to Step 3.

**Step 3: Evaluate validity of specific instances of assays.**
* **Sub-step 3a: Basic Controls and Replicates.**
    * **Internal Judgment:** The paper does not mention specific controls or replicates used in the experiments. However, it states that the results shown in figures are mean values with standard errors from 2-4 independent experiments. This suggests some level of replication.

    * **Internal Decision Logic (for 3a):** Since the paper does not explicitly state whether normal/negative/wild-type and abnormal/positive/null controls were used, we proceed to Sub-step 3b.

* **Sub-step 3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a).**
    * **Internal Judgment:** The paper does not mention any specific validation studies or commercial kits used for the assays. However, it provides detailed methods and results, suggesting that the assays are standard techniques in the field.

    * **Internal Decision Logic (for 3b):** Since the assays appear to be broadly accepted in the field, we assume that the functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

* **Sub-step 3c: Variant Controls (if basic controls/replicates were sufficient in 3a).**
    * **Internal Judgment:** The paper does not mention any specific pathogenic or benign variant controls used in the experiments. However, it states that T175N and T223P were expressed at levels similar to wild-type DJ-1, which may suggest that these variants could serve as variant controls.

    * **Internal Decision Logic (for 3c):** Since the paper does not explicitly mention known pathogenic or benign variant controls, we assume that the functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

**Step 4: Apply evidence to individual variant interpretation.**
* **Sub-step 4a: Statistical Analyses.**
    * **Internal Judgment:** The paper does not provide detailed statistical analyses for the experiments. It only mentions that the results shown in figures are mean values with standard errors from 2-4 independent experiments. This suggests some level of statistical analysis, but not enough to calculate OddsPath.

    * **Internal Decision Logic (for 4a):** Since the statistical analyses are insufficient, we proceed to Sub-step 4b.

* **Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient).**
    * **Internal Judgment:** The paper does not mention any specific pathogenic or benign variant controls used in the experiments. Therefore, we cannot determine the total number of variant controls used across the study.

    * **Internal Decision Logic (for 4b):** Since the total number of variant controls is unknown, we assume that the functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

* **Sub-step 4c: Correlate OddsPath (if statistical analyses were sufficient).**
    * **Internal Judgment:** Since the statistical analyses are insufficient, we cannot extract the OddsPath value calculated in the paper for the A104T variant.

    * **Internal Decision Logic (Typical Outcomes):** Since we cannot correlate the OddsPath, we assume that the functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

**Final Assessment:**
* **Functional Evidence Type:** N/A (since we do not have sufficient information to make a definitive assessment)
* **Functional Evidence Strength:** Max PS3_supporting / Max BS3_supporting
* **Overall Conclusion:** The functional evidence for the A104T variant is considered **Max PS3_supporting / Max BS3_supporting**, as the paper does not provide sufficient information to make a more definitive assessment. However, the lack of explicit statements about the disease mechanism and the use of variant controls weaken the evidence strength.

#### Variant: T223P

**Step 1: Define the disease mechanism.**
* **Internal Judgment:** There is no explicit statement about the disease mechanism or the function of DJ-1 within it. The article focuses on DJ-1 mutations and their effects on protein stability and activity.

**Step 2: Evaluate applicability of general classes of assay used in the field.**
* **Internal Decision Logic:** Since the paper does not provide sufficient information about the disease mechanism, we cannot evaluate the applicability of the general assay class. Therefore, we proceed to Step 3.

**Step 3: Evaluate validity of specific instances of assays.**
* **Sub-step 3a: Basic Controls and Replicates.**
    * **Internal Judgment:** The paper does not mention specific controls or replicates used in the experiments. However, it states that the results shown in figures are mean values with standard errors from 2-4 independent experiments. This suggests some level of replication.

    * **Internal Decision Logic (for 3a):** Since the paper does not explicitly state whether normal/negative/wild-type and abnormal/positive/null controls were used, we proceed to Sub-step 3b.

* **Sub-step 3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a).**
    * **Internal Judgment:** The paper does not mention any specific validation studies or commercial kits used for the assays. However, it provides detailed methods and results, suggesting that the assays are standard techniques in the field.

    * **Internal Decision Logic (for 3b):** Since the assays appear to be broadly accepted in the field, we assume that the functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

* **Sub-step 3c: Variant Controls (if basic controls/replicates were sufficient in 3a).**
    * **Internal Judgment:** The paper does not mention any specific pathogenic or benign variant controls used in the experiments. However, it states that T175N and T223P were expressed at levels similar to wild-type DJ-1, which may suggest that these variants could serve as variant controls.

    * **Internal Decision Logic (for 3c):** Since the paper does not explicitly mention known pathogenic or benign variant controls, we assume that the functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

**Step 4: Apply evidence to individual variant interpretation.**
* **Sub-step 4a: Statistical Analyses.**
    * **Internal Judgment:** The paper does not provide detailed statistical analyses for the experiments. It only mentions that the results shown in figures are mean values with standard errors from 2-4 independent experiments. This suggests some level of statistical analysis, but not enough to calculate OddsPath.

    * **Internal Decision Logic (for 4a):** Since the statistical analyses are insufficient, we proceed to Sub-step 4b.

* **Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient).**
    * **Internal Judgment:** The paper does not mention any specific pathogenic or benign variant controls used in the experiments. Therefore, we cannot determine the total number of variant controls used across the study.

    * **Internal Decision Logic (for 4b):** Since the total number of variant controls is unknown, we assume that the functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

* **Sub-step 4c: Correlate OddsPath (if statistical analyses were sufficient).**
    * **Internal Judgment:** Since the statistical analyses are insufficient, we cannot extract the OddsPath value calculated in the paper for the T223P variant.

    * **Internal Decision Logic (Typical Outcomes):** Since we cannot correlate the OddsPath, we assume that the functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

**Final Assessment:**
* **Functional Evidence Type:** N/A (since we do not have sufficient information to make a definitive assessment)
* **Functional Evidence Strength:** Max PS3_supporting / Max BS3_supporting
* **Overall Conclusion:** The functional evidence for the T223P variant is considered **Max PS3_supporting / Max BS3_supporting**, as the paper does not provide sufficient information to make a more definitive assessment. However, the lack of explicit statements about the disease mechanism and the use of variant controls weaken the evidence strength.

#### Variant: H126R

**Step 1: Define the disease mechanism.**
* **Internal Judgment:** There is no explicit statement about the disease mechanism or the function of DJ-1 within it. The article focuses on DJ-1 mutations and their effects on protein stability and activity.

**Step 2: Evaluate applicability of general classes of assay used in the field.**
* **Internal Decision Logic:** Since the paper does not provide sufficient information about the disease mechanism, we cannot evaluate the applicability of the general assay class. Therefore, we proceed to Step 3.

**Step 3: Evaluate validity of specific instances of assays.**
* **Sub-step 3a: Basic Controls and Replicates.**
    * **Internal Judgment:** The paper does not mention specific controls or replicates used in the experiments. However, it states that the results shown in figures are mean values with standard errors from 2-4 independent experiments. This suggests some level of replication.

    * **Internal Decision Logic (for 3a):** Since the paper does not explicitly state whether normal/negative/wild-type and abnormal/positive/null controls were used, we proceed to Sub-step 3b.

* **Sub-step 3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a).**
    * **Internal Judgment:** The paper does not mention any specific validation studies or commercial kits used for the assays. However, it provides detailed methods and results, suggesting that the assays are standard techniques in the field.

    * **Internal Decision Logic (for 3b):** Since the assays appear to be broadly accepted in the field, we assume that the functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

* **Sub-step 3c: Variant Controls (if basic controls/replicates were sufficient in 3a).**
    * **Internal Judgment:** The paper does not mention any specific pathogenic or benign variant controls used in the experiments. However, it states that T175N and T223P were expressed at levels similar to wild-type DJ-1, which may suggest that these variants could serve as variant controls.

    * **Internal Decision Logic (for 3c):** Since the paper does not explicitly mention known pathogenic or benign variant controls, we assume that the functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

**Step 4: Apply evidence to individual variant interpretation.**
* **Sub-step 4a: Statistical Analyses.**
    * **Internal Judgment:** The paper does not provide detailed statistical analyses for the experiments. It only mentions that the results shown in figures are mean values with standard errors from 2-4 independent experiments. This suggests some level of statistical analysis, but not enough to calculate OddsPath.

    * **Internal Decision Logic (for 4a):** Since the statistical analyses are insufficient, we proceed to Sub-step 4b.

* **Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient).**
    * **Internal Judgment:** The paper does not mention any specific pathogenic or benign variant controls used in the experiments. Therefore, we cannot determine the total number of variant controls used across the study.

    * **Internal Decision Logic (for 4b):** Since the total number of variant controls is unknown, we assume that the functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

* **Sub-step 4c: Correlate OddsPath (if statistical analyses were sufficient).**
    * **Internal Judgment:** Since the statistical analyses are insufficient, we cannot extract the OddsPath value calculated in the paper for the H126R variant.

    * **Internal Decision Logic (Typical Outcomes):** Since we cannot correlate the OddsPath, we assume that the functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

**Final Assessment:**
* **Functional Evidence Type:** N/A (since we do not have sufficient information to make a definitive assessment)
* **Functional Evidence Strength:** Max PS3_supporting / Max BS3_supporting
* **Overall Conclusion:** The functional evidence for the H126R variant is considered **Max PS3_supporting / Max BS3_supporting**, as the paper does not provide sufficient information to make a more definitive assessment. However, the lack of explicit statements about the disease mechanism and the use of variant controls weaken the evidence strength.

#### Variant: A158P

**Step 1: Define the disease mechanism.**
* **Internal Judgment:** There is no explicit statement about the disease mechanism or the function of DJ-1 within it. The article focuses on DJ-1 mutations and their effects on protein stability and activity.

**Step 2: Evaluate applicability of general classes of assay used in the field.**
* **Internal Decision Logic:** Since the paper does not provide sufficient information about the disease mechanism, we cannot evaluate the applicability of the general assay class. Therefore, we proceed to Step 3.

**Step 3: Evaluate validity of specific instances of assays.**
* **Sub-step 3a: Basic Controls and Replicates.**
    * **Internal Judgment:** The paper does not mention specific controls or replicates used in the experiments. However, it states that the results shown in figures are mean values with standard errors from 2-4 independent experiments. This suggests some level of replication.

    * **Internal Decision Logic (for 3a):** Since the paper does not explicitly state whether normal/negative/wild-type and abnormal/positive/null controls were used, we proceed to Sub-step 3b.

* **Sub-step 3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a).**
    * **Internal Judgment:** The paper does not mention any specific validation studies or commercial kits used for the assays. However, it provides detailed methods and results, suggesting that the assays are standard techniques in the field.

    * **Internal Decision Logic (for 3b):** Since the assays appear to be broadly accepted in the field, we assume that the functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

* **Sub-step 3c: Variant Controls (if basic controls/replicates were sufficient in 3a).**
    * **Internal Judgment:** The paper does not mention any specific pathogenic or benign variant controls used in the experiments. However, it states that T175N and T223P were expressed at levels similar to wild-type DJ-1, which may suggest that these variants could serve as variant controls.

    * **Internal Decision Logic (for 3c):** Since the paper does not explicitly mention known pathogenic or benign variant controls, we assume that the functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

**Step 4: Apply evidence to individual variant interpretation.**
* **Sub-step 4a: Statistical Analyses.**
    * **Internal Judgment:** The paper does not provide detailed statistical analyses for the experiments. It only mentions that the results shown in figures are mean values with standard errors from 2-4 independent experiments. This suggests some level of statistical analysis, but not enough to calculate OddsPath.

    * **Internal Decision Logic (for 4a):** Since the statistical analyses are insufficient, we proceed to Sub-step 4b.

* **Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient).**
    * **Internal Judgment:** The paper does not mention any specific pathogenic or benign variant controls used in the experiments. Therefore, we cannot determine the total number of variant controls used across the study.

    * **Internal Decision Logic (for 4b):** Since the total number of variant controls is unknown, we assume that the functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

* **Sub-step 4c: Correlate OddsPath (if statistical analyses were sufficient).**
    * **Internal Judgment:** Since the statistical analyses are insufficient, we cannot extract the OddsPath value calculated in the paper for the A158P variant.

    * **Internal Decision Logic (Typical Outcomes):** Since we cannot correlate the OddsPath, we assume that the functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

**Final Assessment:**
* **Functional Evidence Type:** N/A (since we do not have sufficient information to make a definitive assessment)
* **Functional Evidence Strength:** Max PS3_supporting / Max BS3_supporting
* **Overall Conclusion:** The functional evidence for the A158P variant is considered **Max PS3_supporting / Max BS3_supporting**, as the paper does not provide sufficient information to make a more definitive assessment. However, the lack of explicit statements about the disease mechanism and the use of variant controls weaken the evidence strength.

#### Variant: P158A

**Step 1: Define the disease mechanism.**
* **Internal Judgment:** There is no explicit statement about the disease mechanism or the function of DJ-1 within it. The article focuses on DJ-1 mutations and their effects on protein stability and activity.

**Step 2: Evaluate applicability of general classes of assay used in the field.**
* **Internal Decision Logic:** Since the paper does not provide sufficient information about the disease mechanism, we cannot evaluate the applicability of the general assay class. Therefore, we proceed to Step 3.

**Step 3: Evaluate validity of specific instances of assays.**
* **Sub-step 3a: Basic Controls and Replicates.**
    * **Internal Judgment:** The paper does not mention specific controls or replicates used in the experiments. However, it states that the results shown in figures are mean values with standard errors from 2-4 independent experiments. This suggests some level of replication.

    * **Internal Decision Logic (for 3a):** Since the paper does not explicitly state whether normal/negative/wild-type and abnormal/positive/null controls were used, we proceed to Sub-step 3b.

* **Sub-step 3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a).**
    * **Internal Judgment:** The paper does not mention any specific validation studies or commercial kits used for the assays. However, it provides detailed methods and results, suggesting that the assays are standard techniques in the field.

    * **Internal Decision Logic (for 3b):** Since the assays appear to be broadly accepted in the field, we assume that the functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

* **Sub-step 3c: Variant Controls (if basic controls/replicates were sufficient in 3a).**
    * **Internal Judgment:** The paper does not mention any specific pathogenic or benign variant controls used in the experiments. However, it states that T175N and T223P were expressed at levels similar to wild-type DJ-1, which may suggest that these variants could serve as variant controls.

    * **Internal Decision Logic (for 3c):** Since the paper does not explicitly mention known pathogenic or benign variant controls, we assume that the functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

**Step 4: Apply evidence to individual variant interpretation.**
* **Sub-step 4a: Statistical Analyses.**
    * **Internal Judgment:** The paper does not provide detailed statistical analyses for the experiments. It only mentions that the results shown in figures are mean values with standard errors from 2-4 independent experiments. This suggests some level of statistical analysis, but not enough to calculate OddsPath.

    * **Internal Decision Logic (for 4a):** Since the statistical analyses are insufficient, we proceed to Sub-step 4b.

* **Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient).**
    * **Internal Judgment:** The paper does not mention any specific pathogenic or benign variant controls used in the experiments. Therefore, we cannot determine the total number of variant controls used across the study.

    * **Internal Decision Logic (for 4b):** Since the total number of variant controls is unknown, we assume that the functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

* **Sub-step 4c: Correlate OddsPath (if statistical analyses were sufficient).**
    * **Internal Judgment:** Since the statistical analyses are insufficient, we cannot extract the OddsPath value calculated in the paper for the P158A variant.

    * **Internal Decision Logic (Typical Outcomes):** Since we cannot correlate the OddsPath, we assume that the functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

**Final Assessment:**
* **Functional Evidence Type:** N/A (since we do not have sufficient information to make a definitive assessment)
* **Functional Evidence Strength:** Max PS3_supporting / Max BS3_supporting
* **Overall Conclusion:** The functional evidence for the P158A variant is considered **Max PS3_supporting / Max BS3_supporting**, as the paper does not provide sufficient information to make a more definitive assessment. However, the lack of explicit statements about the disease mechanism and the use of variant controls weaken the evidence strength.

**Final Output:**
```json
{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "C106A",
        "Protein_Change": {
          "ref": "C",
          "alt": "A",
          "position": "106"
        },
        "variant_string_id": "C106A"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The article focuses on DJ-1 mutations and their effects on protein stability and activity",
          "judgment": "No",
          "reasoning": "No explicit statement about the disease mechanism or the function of DJ-1 within it"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper does not provide sufficient information about the disease mechanism, so we cannot evaluate the applicability of the general assay class",
          "judgment": "No",
          "reasoning": "Cannot evaluate applicability of the general assay class without knowing the disease mechanism",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The paper does not mention specific controls or replicates used in the experiments",
          "judgment": "No",
          "reasoning": "Cannot evaluate validity of specific instances of assays without information on basic controls and replicates",
          "next_step_or_outcome": "Proceed to Sub-step 3b"
        },
        {
          "step_name": "Sub-step 3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a)",
          "extracted_paper_info": "The paper does not mention any specific validation studies or commercial kits used for the assays, but provides detailed methods and results, suggesting that the assays are standard techniques in the field",
          "judgment": "Yes",
          "reasoning": "Assuming that the assays are broadly accepted in the field",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "N/A",
        "strength": "Max PS3_supporting / Max BS3_supporting"
      },
      "overall_conclusion": "The functional evidence for the C106A variant is considered Max PS3_supporting / Max BS3_supporting, as the paper does not provide sufficient information to make a more definitive assessment. However, the lack of explicit statements about the disease mechanism and the use of variant controls weaken the evidence strength."
    },
    {
      "variant_id": {
        "Gene": "M26I",
        "Protein_Change": {
          "ref": "M",
          "alt": "I",
          "position": "26"
        },
        "variant_string_id": "M26I"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The article focuses on DJ-1 mutations and their effects on protein stability and activity",
          "judgment": "No",
          "reasoning": "No explicit statement about the disease mechanism or the function of DJ-1 within it"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper does not provide sufficient information about the disease mechanism, so we cannot evaluate the applicability of the general assay class",
          "judgment": "No",
          "reasoning": "Cannot evaluate applicability of the general assay class without knowing the disease mechanism",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The paper does not mention specific controls or replicates used in the experiments",
          "judgment": "No",
          "reasoning": "Cannot evaluate validity of specific instances of assays without information on basic controls and replicates",
          "next_step_or_outcome": "Proceed to Sub-step 3b"
        },
        {
          "step_name": "Sub-step 3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a)",
          "extracted_paper_info": "The paper does not mention any specific validation studies or commercial kits used for the assays, but provides detailed methods and results, suggesting that the assays are standard techniques in the field",
          "judgment": "Yes",
          "reasoning": "Assuming that the assays are broadly accepted in the field",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "N/A",
        "strength": "Max PS3_supporting / Max BS3_supporting"
      },
      "overall_conclusion": "The functional evidence for the M26I variant is considered Max PS3_supporting / Max BS3_supporting, as the paper does not provide sufficient information to make a more definitive assessment. However, the lack of explicit statements about the disease mechanism and the use of variant controls weaken the evidence strength."
    },
    {
      "variant_id": {
        "Gene": "T175N",
        "Protein_Change": {
          "ref": "T",
          "alt": "N",
          "position": "175"
        },
        "variant_string_id": "T175N"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The article focuses on DJ-1 mutations and their effects on protein stability and activity",
          "judgment": "No",
          "reasoning": "No explicit statement about the disease mechanism or the function of DJ-1 within it"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper does not provide sufficient information about the disease mechanism, so we cannot evaluate the applicability of the general assay class",
          "judgment": "No",
          "reasoning": "Cannot evaluate applicability of the general assay class without knowing the disease mechanism",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The paper does not mention specific controls or replicates used in the experiments",
          "judgment": "No",
          "reasoning": "Cannot evaluate validity of specific instances of assays without information on basic controls and replicates",
          "next_step_or_outcome": "Proceed to Sub-step 3b"
        },
        {
          "step_name": "Sub-step 3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a)",
          "extracted_paper_info": "The paper does not mention any specific validation studies or commercial kits used for the assays, but provides detailed methods and results, suggesting that the assays are standard techniques in the field",
          "judgment": "Yes",
          "reasoning": "Assuming that the assays are broadly accepted in the field",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "N/A",
        "strength": "Max PS3_supporting / Max BS3_supporting"
      },
      "overall_conclusion": "The functional evidence for the T175N variant is considered Max PS3_supporting / Max BS3_supporting, as the paper does not provide sufficient information to make a more definitive assessment. However, the lack of explicit statements about the disease mechanism and the use of variant controls weaken the evidence strength."
    },
    {
      "variant_id": {
        "Gene": "L166P",
        "Protein_Change": {
          "ref": "L",
          "alt": "P",
          "position": "166"
        },
        "variant_string_id": "L166P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The article focuses on DJ-1 mutations and their effects on protein stability and activity",
          "judgment": "No",
          "reasoning": "No explicit statement about the disease mechanism or the function of DJ-1 within it"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper does not provide sufficient information about the disease mechanism, so we cannot evaluate the applicability of the general assay class",
          "judgment": "No",
          "reasoning": "Cannot evaluate applicability of the general assay class without knowing the disease mechanism",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The paper does not mention specific controls or replicates used in the experiments",
          "judgment": "No",
          "reasoning": "Cannot evaluate validity of specific instances of assays without information on basic controls and replicates",
          "next_step_or_outcome": "Proceed to Sub-step 3b"
        },
        {
          "step_name": "Sub-step 3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a)",
          "extracted_paper_info": "The paper does not mention any specific validation studies or commercial kits used for the assays, but provides detailed methods and results, suggesting that the assays are standard techniques in the field",
          "judgment": "Yes",
          "reasoning": "Assuming that the assays are broadly accepted in the field",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "N/A",
        "strength": "Max PS3_supporting / Max BS3_supporting"
      },
      "overall_conclusion": "The functional evidence for the L166P variant is considered Max PS3_supporting / Max BS3_supporting, as the paper does not provide sufficient information to make a more definitive assessment. However, the lack of explicit statements about the disease mechanism and the use of variant controls weaken the evidence strength."
    },
    {
      "variant_id": {
        "Gene": "A104T",
        "Protein_Change": {
          "ref": "A",
          "alt": "T",
          "position": "104"
        },
        "variant_string_id": "A104T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The article focuses on DJ-1 mutations and their effects on protein stability and activity",
          "judgment": "No",
          "reasoning": "No explicit statement about the disease mechanism or the function of DJ-1 within it"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper does not provide sufficient information about the disease mechanism, so we cannot evaluate the applicability of the general assay class",
          "judgment": "No",
          "reasoning": "Cannot evaluate applicability of the general assay class without knowing the disease mechanism",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The paper does not mention specific controls or replicates used in the experiments",
          "judgment": "No",
          "reasoning": "Cannot evaluate validity of specific instances of assays without information on basic controls and replicates",
          "next_step_or_outcome": "Proceed to Sub-step 3b"
        },
        {
          "step_name": "Sub-step 3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a)",
          "extracted_paper_info": "The paper does not mention any specific validation studies or commercial kits used for the assays, but provides detailed methods and results, suggesting that the assays are standard techniques in the field",
          "judgment": "Yes",
          "reasoning": "Assuming that the assays are broadly accepted in the field",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "N/A",
        "strength": "Max PS3_supporting / Max BS3_supporting"
      },
      "overall_conclusion": "The functional evidence for the A104T variant is considered Max PS3_supporting / Max BS3_supporting, as the paper does not provide sufficient information to make a more definitive assessment. However, the lack of explicit statements about the disease mechanism and the use of variant controls weaken the evidence strength."
    },
    {
      "variant_id": {
        "Gene": "T223P",
        "Protein_Change": {
          "ref": "T",
          "alt": "P",
          "position": "223"
        },
        "variant_string_id": "T223P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The article focuses on DJ-1 mutations and their effects on protein stability and activity",
          "judgment": "No",
          "reasoning": "No explicit statement about the disease mechanism or the function of DJ-1 within it"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper does not provide sufficient information about the disease mechanism, so we cannot evaluate the applicability of the general assay class",
          "judgment": "No",
          "reasoning": "Cannot evaluate applicability of the general assay class without knowing the disease mechanism",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The paper does not mention specific controls or replicates used in the experiments",
          "judgment": "No",
          "reasoning": "Cannot evaluate validity of specific instances of assays without information on basic controls and replicates",
          "next_step_or_outcome": "Proceed to Sub-step 3b"
        },
        {
          "step_name": "Sub-step 3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a)",
          "extracted_paper_info": "The paper does not mention any specific validation studies or commercial kits used for the assays, but provides detailed methods and results, suggesting that the assays are standard techniques in the field",
          "judgment": "Yes",
          "reasoning": "Assuming that the assays are broadly accepted in the field",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "N/A",
        "strength": "Max PS3_supporting / Max BS3_supporting"
      },
      "overall_conclusion": "The functional evidence for the T223P variant is considered Max PS3_supporting / Max BS3_supporting, as the paper does not provide sufficient information to make a more definitive assessment. However, the lack of explicit statements about the disease mechanism and the use of variant controls weaken the evidence strength."
    },
    {
      "variant_id": {
        "Gene": "H126R",
        "Protein_Change": {
          "ref": "H",
          "alt": "R",
          "position": "126"
        },
        "variant_string_id": "H126R"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The article focuses on DJ-1 mutations and their effects on protein stability and activity",
          "judgment": "No",
          "reasoning": "No explicit statement about the disease mechanism or the function of DJ-1 within it"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper does not provide sufficient information about the disease mechanism, so we cannot evaluate the applicability